Management of high serum cholesterol and related disorders in patients at risk for coronary heart disease

American Journal of Medicine

Volumn 102, Issue 2 A, 1997, Pages 15-22

  Grundy, Scott M ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PRAVASTATIN; SIMVASTATIN;

CHOLESTEROL METABOLISM; CLINICAL TRIAL; CORONARY RISK; DRUG EFFICACY; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; META ANALYSIS; MULTICENTER STUDY; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; RISK MANAGEMENT; SECONDARY PREVENTION;

EID: 0030887283     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(97)00462-2     Document Type: Article

References (21)

1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. National Cholesterol Education Program: second report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). Circulation. 1994; 89:1329-1445.
2. Johnson CL, Rifkind BM, Sempos CT, et al. Declining serum total cholesterol levels among US adults: the National Health and Nutrition Examination Surveys. JAMA. 1993;269:3002-3008.
3. Strong JP, McGill HC Jr. The natural history of coronary atherosclerosis. Am J Pathol. 1962;40:37-49.
4. Rossouw JE, Lewis B, Rifkind BM. The value of lowering cholesterol after myocardial infarction. N Engl J Med. 1990;323:1112-1119.
5. Buchwald H, Varco RL, Matts JP, et al. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hyper-cholesterolemia. Report of the Program on the Surgical Control of Hyperlipidemias (POSCH). N Engl J Med. 1990;323:946-955.
6. Brown BG, Zhao X-Q, Sacco DE, Albers JJ. Lipid lowering and plaque regression: new insights into prevention of plaque disruption and clinical events in coronary disease. Circulation. 1993;87:1781-1791.
7. Byington RP, Jukema JW, Salonen JT, et al. Reduction in cardiovascular events during pravastatin therapy. Pooled analysis of clinical events of the pravastatin atherosclerosis intervention program. Circulation. 1995;92:2419-2425.
8. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
9. Sacks FM, Pfeffer MA, Moye LA, et al for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001-1009.
10. Campeau L, Hunninghake DB, Domanski MJ. Post-CABG Trial: design and results. Reported at the American College of Cardiology 45th Scientific Session, Orlando, FL: March 24-26, 1996.
11. Smith SC, Blair SN, Criqui MH, et al, Secondary Prevention Panel. Preventing heart attack and death in patients with coronary disease. Circulation. 1995;92:2-4.
12. Denke MA, Grundy SM. Efficacy of low-dose cholesterol-lowering drug therapy in men with moderate hypercholesterolemia. Arch Intern Med. 1995;155:393-399.
13. Lipid Research Clinics Program. The Lipid Research Clinics coronary primary prevention trial results: I. Reduction in the incidence of coronary heart disease. JAMA. 1984;251:351-364.
14. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial Results: II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA. 1984; 251:365-374.
15. Vega GL, Grundy SM. Treatment of primary moderate hypercholesterolemia with lovastatin (mevinolin) and colestipol. JAMA. 1987;257:33-38.
16. Vega GL, Grundy SM. Lipoprotein responses to treatment with lovastatin, gemfibrozil, and nicotinic acid in normolipidemic patients with hypoalphalipoproteinemia. Arch Intern Med. 1994;154:73-82.
17. Martin-Jadraque R, Tato F, Mostaza JM, et al. Effectiveness of low-dose crystalline nicotinic acid in men with low high-density lipoprotein cholesterol levels. Arch Intern Med. 1996;156:1081-1088.
18. East C, Bilheimer DW, Grundy SM. Combination drug therapy for familial combined hyperlipidemia. Ann Intern Med. 1988;109:25-32.
19. Frick MH, Elo MO, Haapa K, et al. Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med. 1987;317:1237-1245.
20. Shepherd J, Cobbe SM, Ford I, et al for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333:1301-1307.
21. PDAY Research Group. Natural history of aortic and coronary atherosclerotic lesions in youth - findings from the PDAY study. Arterioscler Thromb. 1993;13:1291-1298.